GlassScriptPhysician profile
Aaron M Pierce
NPI 1477842896
$6,358.29
in general payments reported to CMS, 2019-2025
30 companies · $1,164 in 2025
The $1,164 reported for 2025 was more than what a typical Sleep Medicine (Internal Medicine) provider received nationally (typical 2025 total: $447).
See the full distribution for Sleep Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,524 · 2020: $300 · 2021: $124 · 2022: $897 · 2023: $1,523 · 2024: $827 · 2025: $1,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,815 · Consulting Fee: $350 · Travel and Lodging: $206 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,814.84 |
| Consulting Fee | $350.00 |
| Travel and Lodging | $205.62 |
| Education | $143.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,701.26 | 2020-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $913.62 | 2019-2025 | |
| Harmony Biosciences LLC | $663.85 | 2022-2024 | Wakix |
| Axsome Therapeutics, INC. | $538.52 | 2022-2024 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $310.12 | 2024-2025 | Lumryz |
| Zoll Respicardia, INC. | $292.98 | 2023-2025 | Remede System |
| Mylan Specialty L.P. | $279.53 | 2019 | |
| Merck Sharp & Dohme LLC | $241.11 | 2022-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.87 | 2019 | |
| Idorsia Pharmaceuticals US INC | $164.29 | 2022-2024 | Quviviq |
| Regeneron Healthcare Solutions, INC. | $138.62 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.83 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $84.41 | 2019 | |
| Mayne Pharma Commercial LLC | $84.40 | 2019 | |
| Ucb, INC. | $74.52 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $67.61 | 2019 | |
| Itamar Medical INC | $64.02 | 2023 | Watchpatone |
| Electromed, INC. | $63.86 | 2019 | |
| Shire North American Group INC | $56.49 | 2019 | |
| Philips North America LLC | $53.92 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $53.02 | 2019 | |
| Fisher & Paykel Healthcare INC | $42.68 | 2022-2024 | Fisher & Paykel Healthcare |
| Arbor Pharmaceuticals, INC. | $34.62 | 2019 | |
| 3b Medical, INC. | $31.54 | 2025 | Luna |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.38 | 2024 | Lifevest |
| Daiichi Sankyo INC. | $25.78 | 2024 | Injectafer |
| Vapotherm INC | $25.00 | 2019 | |
| Circassia INC. | $18.56 | 2019 | |
| Phadia US INC. | $13.03 | 2019 | |
| Insmed, INC. | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.